Join Bill Harrington and Allen Chen of OUP’s investment team for a discussion on startup financing trends to review the state of the venture funding landscape. We covered current market behaviors across the entire startup ecosystem with a specific emphasis on university spinouts. Bill Harrington outlined trends in the life sciences, including biopharma, research tools,…
Join Nabil Ullah and Justin Robeny of OUP’s investment team for a discussion on startup financing trends to review the state of the venture funding landscape. They cover current market behaviors across the entire startup ecosystem with a specific emphasis on university spinouts. Justin Robeny outlines trends in the life sciences, including biopharma, research tools,…
OUP is pleased to invite you to our annual startup financing trends webinar. Join Harry Won, Nii Dodoo-Amoo and Nabil Ullah of OUP’s investment team for a discussion on startup financing trends to review the state of the venture funding landscape. We’ll cover current market behaviors across the entire startup ecosystem with a specific emphasis…
We spoke with Tech Managing Partner Marc Singer and our Life Science Principal Mitra Miri for their perspectives on diligencing VCs, having multiple investors in a round, and red flags to look for in a potential VC partner. While some of their insights were similar, as with all individuals in the venture capital space, they did have differing opinions.
Here are some key takeaways from our webinar on recent university startup financing trends. For more exclusive financing data around university startups, watch the full webinar below.
We spoke with our Tech Associate, Ajay Rayasam, and our Life Science Associate, Margalit Haber, for their perspectives on how best to initially interact with VCs. While some of their insights were similar, as with all individuals in the venture capital space, they did have differing opinions.
In late 2020, OUP hosted a webinar on Angel and Accelerator Funding for University Startups. We reconnected with two of the panelists, Ashok Kamal, Executive Director of Tech Coast Angels, and Jun Axup, Chief Science Officer and Partner of IndieBio, to continue the conversation about angel and accelerator funding in addition to answering some follow-up…
Corporate VCs have played a crucial role in financing life sciences companies for decades, but have you ever wondered what, if anything, makes them different from institutional venture capital funds? Join us for this webinar as we talk to a panel of investors at industry-leading CVC funds to learn more about their strategies, investment criteria, and how they measure success.
In January of 2020, the U.S. Federal Government issued final rules fully implementing the new powers granted to the Committee on Foreign Investment in the United States (CFIUS). Effective February 13, 2020, the Committee started to exercise its expanded ability to review the national security implications of more foreign investments – in particular companies with ‘novel or advanced technology’ including biotechnology, artificial intelligence, robotics, quantum computing, and advanced materials. New mandatory filing rules are now in place, and the Committee’s new enforcement team – charged with finding unfiled cases within CFIUS’s jurisdiction – is now bringing in far more cases than ever before.
A common practice across universities that hold equity in a company that IPOs is to sell all of its shares as soon as the lock up expires. But do the best returns necessarily come from selling all your stock immediately? When is the right time to sell stock in a therapeutics company?